The panel has also reappointed three commissioners whose four-year terms expired this year.
The CHM encourages the gathering and examination of data pertaining to adverse reactions for human medications and offers independent expert advice to ministers on the safety, quality, and efficacy of medicines.
Sponsored by the Department of Health and Social Care, it is a non-departmental public advisory group.
the following nine new commissioners:
Southampton University’s Professor Tony Williams, an authority on translational medicine
Professor David Hunt, senior clinical fellow at the Wellcome Trust, head of neuroinflammation medicine, University of Edinburgh
Professor David Dockrell, director of the Centre for Inflammation Research and chair of infection medicine at the University of Edinburgh
Dr. Gerri Mortimore, a post-registration health care associate professor at the University of Derby
Clinical toxicology professor at King’s College London and consultant physician at Guy’s and St. Thomas’ NHS Foundation Trust is Professor Paul Dargan.
Dr. Vanessa Raymont, senior clinical researcher at the University of Oxford, is also the trust’s honorary consultant and the R&D director.
Julia Cons, independent chair of NHS England’s National Individual Funding Request Panel
Professor David Moore is a consultant physician at the UCLH Hospital for Tropical Diseases and a professor of infectious diseases and tropical medicine at the London School of Hygiene & Tropical Medicine.
Susan Bradford, Professor Jamie Coleman, and Dr. Jamie Fraser have also been reappointed to new terms on the CHM, together with Professor Rui Providencia, associate professor, Institute of Health Informatics, University College London.
The CHM’s Chair, Professor Sir Munir Pirmohamed, stated:
I’m happy to welcome nine new Commissioners to the CHM. Each one of them brings a wealth of knowledge to the table, and together they strengthen the impartial counsel we offer ministers.
I also want to express my gratitude to the current commissioners, particularly those who have just been reappointed, for continuing to devote their time and knowledge to our crucial talks on the security and efficiency of critical medications in addition to their regular work.